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Breast cancer and specific types of combined oral contraceptives
D.B. Thomas, E.A. Noonan, and the WHO Collaborative Study of Neoplasia and Steroid
Contraceptives*
Summary Data on 2,754 cases and 18,565 controls from a multinational hospital-based, case-control study
were analysed to determine whether observed associations between combined oral contraceptives and breast
cancer are similar for oral contraceptives with varying types and doses of oestrogens and progestins. After
stratifying on duration of use, risk was found to be increased in current and recent users, and to decline with
time since last use. These associations, of similar strength, were observed for users of products that contain
mestranol and ethinyl estradiol, for women who used preparations with progestins derived from 19-nor-
testosterone and 17-alpha-hydroxyprogesterone, and for those who took preparations with relatively higher
and lower doses of oestrogen. When products with equal doses of the same oestrogen or progestin and varying
doses of the other hormonal constituent were considered, slightly higher relative risks per year of use were
estimated for users of products with relatively higher than lower doses of either the constituent oestrogen or
progestin, but the differences in relative risk could readily have occurred by chance. This study provides no
evidence that risk of breast cancer in users of oral contraceptives varies by the type of oestrogen or progestin
consumed.
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The possible influence of combined oral contraceptive use on
risk of breast cancer has been studied extensively during the
past two decades, and the existing evidence has been
reviewed on multiple occasions (e.g., Thomas, 1991). Results
ofepidemiologic studies have yielded inconsistent results, and
it cannot be concluded with certainty that these hormonal
preparations alter risk of breast cancer. If they do, the
observed effect has been small.
Most studies have considered combined oral contraceptives
to be a single entity, but they are actually a heterogeneous
group of products that vary in both type and dose of oestro-
gen and progestin, and it is reasonable to expect that their
influence on risk of breast cancer would not be uniform.
Differences in the products under study could therefore be an
explanation for the inconsistent results among studies; and
the observation of only small increases in risk could be a
result of those formulations that are carcinogenic for the
human breast constituting a small proportion of all oral
contraceptives.
The attempts that have been made to assess possible
associations between breast cancer and specific types or
groups of combined oral contraceptives have not yielded
consistent results. In 1983, Pike et al. observed a particularly
strong association between breast cancer and use before the
age of 25 years of oral contraceptives with high progestin
potency as determined by the delay of menses test; but this
was not confirmed in two other studies (Stadel et al., 1985;
Miller et al., 1986), and the validity of the classification that
Pike used has been questioned (Armstrong, 1986). Two
studies have failed to show associations between breast
cancer and use at any time of oral contraceptives with
specific types of progestins (CASH, 1986; Vessey et al., 1989).
McPherson et al. (1987) reported an increase in risk of
breast cancer with duration of use before the birth of a
woman's first child of oral contraceptives that contain ethinyl
estradiol, but not that contain mestranol; but this was not
confirmed in two subsequent studies (Vessey et al., 1989; Paul
et al., 1990a). Also, no differences in relative risks in relation
to overall duration of use of preparations with ethinyl
estradiol and mestranol were observed in three separate
studies (CASH, 1986; UK National, 1989; Vessey et al.,
1989). Similarly, no consistent increases in risk in relation to
specific types of oral contraceptives were observed among
five different investigations (CASH, 1986; Miller et al., 1989;
UK National Group, 1989; Vessey, 1989; Ravnihar et al.,
1988). In addition, relative risks were not consistently greater
in relation to individual formulations with high doses of
oestrogen than in relation to those with lower doses,
although in the UK National Case-Control Study (1989), a
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higher relative risk was observed in women who had used
oral contraceptives with more than 50 micrograms of oestro-
gen (either ethinyl estradiol or mestranol) for over 8 years
than in women who had used lower dose preparations for the
same length of time.
The studies to date have reported results largely in relation
to use of oral contraceptives that contain progestins that are
derivatives of 19-nor-testosterone. None have studied oral
contraceptives that contain derivatives of 17-alpha hydroxy-
progesterone (i.e., medroxyprogesterone acetate and
chloramadinone); and it is these progestins that have been
shown to cause breast cancer in beagles (Fraser & Holck,
1983). Also, estimates of relative risks of breast cancer in
relation to the newer lower dose oral contraceptives have not
been compared with estimates for the older, higher dose
preparations. Data from this multinational study include in-
formation on use of a wide range of formulations, and
provide an opportunity to address these two issues. In addi-
tion, we have attempted to confirm the results of previous
studies, and present results of analyses to assess associations
between breast cancer and specific individual oral contracep-
tives, and oral contraceptives with specific types of oestro-
gens and progestins.
Methods
The methods used in this study have been previously
described (WHO Collaborative Study of Neoplasia and
Steroid Contraceptives, 1990). Data were collected in 12
participating centres in Australia, Chile, the Peoples Republic
of China, Colombia, The German Democratic Republic
(GDR), Israel, Kenya, Mexico, the Philippines, and Thai-
land. Data were collected from thee separate centres in Thai-
land (Siriraj and Chulalongkorn in Bangkok and Chiang
Mai). Data collection began in the various centres between
October 1979 and November 1982 and ceased between
September 1984 and September 1988.
In each hospital, cases were detected by monitoring all new
admissions to wards where women with breast cancer were
treated, and by checking outpatient gynecological and
tumour clinics, and records of hospital pathology
laboratories. Cases included all women diagnosed locally as
having a malignant breast tumour, born either after 1924 or
after 1929 (depending on when oral contraceptives were first
locally available), and who resided during the preceding year
in a defined geographic area served by the hospital.
Controls were selected from among women admitted to
other than obstetric and gynecologic wards, who met the
same age and residential criteria for eligibility as the cases,
and who were not admitted for treatment of conditions
considered a priori to possibly alter contraceptive practices
(i.e., circulatory and cardiovascular diseases, diabetes,
chronic renal disease, benign breast disease, a previously
diagnosed malignancy, chronic liver disease, and any obstet-
ric or gynecologic condition).
Approximately two controls were selected for each case, but
controls were not matched to individual cases. As this was a
study of cancers in addition to those of the breast (i.e., cervix
and corpus uteri, ovary, and liver), more than two controls
per breast cancer case were available for analysis.
A standardised questionnaire was administered in person
to all study subjects to obtain information on the known and
suspected risk factors for the neoplasms under study, and a
complete obstetric and contraceptive history. A calendar and
samples of locally available oral contraceptives were used to
facilitate recall of times of use and products taken. In addi-
tion, the medical records of women who gave a history of
oral contraceptive use were reviewed when available, and in
such instances information from both interviews and these
records were utilised by the interviewers to record details of
the woman's use. The questionnaire was printed in the local
language in all countries except Kenya where multiple langu-
ages are spoken, and the Philippines and Australia, where
English is widely used. Where the information was not
recorded directly on the English version questionnaire, it was
transcribed onto an English version for mailing to the coor-
dinating centre in Seattle.
Pathologists at each centre were responsible for provisional
histological diagnosis of the cases. Slides from all cases were
sent to a single reference pathologist for confirmation of
diagnosis and uniform histologic classification according to
the WHO histologic classification of breast tumours (World
Health Organisation, 1981). Only data from cases considered
by the reference pathologist to have invasive carcinoma of
the breast were utilised for this report.
Of the 2,996 eligible cases and 20,216 controls selected for
this study, 2,835 (94.6%) and 19,221 (95.1%) were inter-
viewed, respectively. As described subsequently, estimates of
relative risks in users of oral contraceptives were controlled
for variables that appeared to confound the relationship
between breast cancer and these products. Eighty-one cases
and 656 controls were excluded from the analyses because
values for one or more of the identified confounders were
missing or the duration of al episodes of oral contraceptive
use was unknown. Of the remaining 2,754 cases, 70.1%,
10.8% and 4.9% had carcinomas classified as ductal, lobular,
and apocrine, respectively; the remaining 14.2% had one of
15 other histologic types.
Since cases tended to be older than controls, and since
both the ratio of controls to cases and the prevalence of use
of oral contraceptives varied among the centres, all relative
risk estimates were controlled for age and centre. Uncondi-
tional logistic regression analyses (Breslow & Day, 1980,
pages 192-246) were utilised to estimate relative risks,
adjusted for these and other potentially confounding
variables. These variables were entered into the regression
models as categorical variables. To control for multiple fac-
tors simultaneously, a final model containing confounding
variables was constructed. Variables were entered into
models sequentially, one at a time, and retained if the
associated chi-square test for goodness of fit was significant
(P <0.05) and if the resultant relative risk in relation to ever
use oral contraceptives was altered by more than 5%. This
model was then used to estimate relative risks of breast
cancer and their 95% confidence intervals in users of various
types of oral contraceptives.
To assess possible relationships of individual formulations
to risk of breast cancer, months of use of the specific oral
contraceptive under consideration, and total months of use
of all other types combined, were included in logistic models
as single continuous variables, and relative risks per year of
use were estimated. Although time since first use was more
strongly related to risk of breast cancer than duration of use,
these two features of exposure were strongly correlated in
our data, and relative risk for year of use thus provides a
valid index by which individual types of oral contraceptives
can be compared, that makes maximum use of the inform-
ation on each episode of use.
Results
As reported in a previous publication (WHO Collaborative
Study of Neoplasia and Steroid Contraceptives, 1990), risk
was observed to be increased in current and recent users of
oral contraceptives, and to decline with time since last use in
all categories of duration, but no trend with months of use
was observed after stratifying on months since last use. As
shown in Table I, these findings were also equally evident in
users of mestranol and ethinyl oestradiol containing oral
contraceptives and the relative risk estimates are not con-
sistently higher for one class of preparations than for the
other.
Relative risks in women who used oral contraceptives
before the birth of their first child for more than 1 year were
estimated to be 2.06 (1.01, 4.17) and 1.19 (0.62, 2.31) in users
of mestranol and ethinyl oestradiol containing products,
respectively. These values are based on small numbers of
users, and their difference could have occurred by chance.110 D.B. THOMAS et al.
Relative risks in women who used mestranol and ethinyl
oestradiol containing formulations before age 25 were
estimated respectively, to be 1.05 (0.82, 1.34) and 1.10 (0.88,
1.36) for ever-users, and 1.78 (1.00, 3.19) and 1.81 (1.15,
2.84) for women who used these products for over 3 years
before age 25. Relative risk estimates did not vary
significantly among women who had used individual formul-
ations before age 25, but all such estimates were based in
small numbers of users and had wide confidence limits.
Table II shows relative risks in relation to duration of use
and months since last use of oral contraceptives that contain
various types of progestins. Relative risks tend to increase
with duration of use of all progestins shown except
ethynodial diacetate, and to decrease with time since last
exposure to all progestin types. Small numbers of users pre-
cluded simultaneous consideration of these two features of
use. There were too few users of oral contraceptives that
contain norethynodrel and medroxyprogesterone acetate to
allow estimates of relative risks in relation to duration or
recency of their use; relative risks in women who ever used
oral contraceptives with these progestins were estimated to be
0.94 (0.38, 2.32) and 1.30 (0.66, 2.57), based on seven and 13
Table I Relative risksa of breast cancer in relation to months of use and months since last use of oral contraceptives
containing mestranol and ethinyl estradiol
Months since Months of use
last use 1-12 13-36 37-84 >84 All users
ethinyl estradiol
<, 3b 1.06 (0.55, 2.07) 1.12 (0.66, 1.90) 1.78 (1.24, 2.55) 1.52 (1.12, 2.07) 1.46 (1.18, 1.82)
[10,163] [17,194] [45,200] [67,203] [139,760]
4-36 1.83 (1.19, 2.81) 1.37 (0.85, 2.21) 1.48 (0.98, 2.22) 1.34 (0.89, 2.03) 1.48 (1.18, 1.86)
[29,224] [23,160] [33,151] [34,118] [119,653]
37-108 0.81 (0.58, 1.14) 1.29 (0.92, 1.80) 1.36 (1.03, 1.80) 1.28 (0.82, 1.99) 1.15 (0.96, 1.38)
[42,468] [48,269] [75,303] [28,114] [193,1154]
>108 0.92 (0.71, 1.20) 0.87 (0.61, 1.25) 1.00 (0.63, 1.58) 1.00 (0.23, 4.34) 0.92 (0.75, 1.12)
[70,618] [37,319] [23,161] [2,20] [132,1118]
All times 0.98 (0.81, 1.19) 1.10 (0.90, 1.36) 1.38 (1.14, 1.68) 1.39 (1.11, 1.74) 1.18 (1.04, 1.33)
[151,1473] [925,942] [176,815] [131,455] [583,3685]
mestranol
<4b 3.31 (1.32, 8.33) 1.41 (0.48, 4.12) 1.34 (0.46, 3.87) 1.75 (0.92, 3.34) 1.70 (1.23, 2.35)
[6,48] [4,48] [4,44] [13,62] [27,202]
4-36 1.29 (0.70, 2.39) 1.62 (0.80, 3.29) 0.72 (0.28, 1.85) 2.72 (1.42, 5.24) 1.45 (1.02, 2.06)
[13,147] [10,80] [5,73] [14,42] [42,342]
37-108 1.36 (0.97, 1.89) 0.89 (0.54, 1.46) 1.66 (1.13, 2.44) 1.76 (1.03, 2.99) 1.34 (1.07, 1.66)
[47,378] [19,203] [38,187] [20,82] [124,850]
> 108 0.95 (0.73, 1.23) 0.90 (0.67, 1.21) 1.01 (0.74, 1.36) 1.05 (0.64, 1.73) 0.90 (0.75, 1.08)
[81,586] [63,343] [63,289] [21,284] [228,1342]
All times 1.13 (0.93, 1.37) 0.97 (0.76, 1.24) 1.17 (0.93, 1.48) 1.58 (1.18, 2.11) 1.15 (1.00, 1.32)
[147,1159] [96,674] [110,593] [68,310] [421,2736]
aAdjusted for age, centre, total pregnancies, socioeconomic index, use of an IUD. All risks are relative to nonusers
of any type of oral contraceptives (based on 1,746 cases and 11,805 controls). 95% confidence intervals are in ( ),
and number of cases and controls are in [ ]. bIncludes current users.
Table II Relative risksa of breast cancer in relation to months of use and months since last use of oral contraceptives containing various
progestins
Months Chlormadinone Norethisterone Ethynodial
of use acetate acetate Norethisterone diacetate Lynestrenol DL-norgestrol
1-12 1.01 (0.71, 1.44) 1.03 (0.75, 1.42) 1.04 (0.79, 1.37) 1.50 (1.04, 2.17) 0.79 (0.48, 1.28) 1.06 (0.86, 1.32)
[54,150] [58,275] [63,851] [42,184] [19,280] [117,1170]
13-36 0.72 (0.49, 1.05) 1.02 (0.74, 1.42) 1.18 (0.82, 1.69) 0.74 (0.43, 1.29) 0.73 (0.38, 1.39) 1.29 (1.01, 1.64)
[45,161] [57,229] [37,405] [16,114] [11,149] [98,703]
37-60/>37 1.10 (0.73, 1.66) 1.19 (0.83, 1.70) 1.50 (1.15, 1.96) 1.10 (0.66, 1.83) 1.45 (0.95, 2.22) 1.30 (1.04, 1.61)
[41,97] [50,152] [76,544] [21,92] [28,180] [127,738]
>60 1.12 (0.78, 1.62) 1.17 (0.88, 1.55)
[42,115] [85,246]
Months since
last use
<4 2.14 (0.77, 5.93) 1.63 (1.09, 2.44) 2.06 (1.45, 2.93) 2.04 (0.75, 5.51) 1.93 (1.00, 3.71) 1.30 (0.99, 1.70)
[7,9] [40,96] [43,300] [6,23] [11,102] [77,552]
4-36 1.95 (0.95, 4.02) 1.27 (1.09, 2.44) 1.14 (0.74, 1.76) 1.85 (0.93, 3.68) 1.69 (0.90, 3.17) 1.57 (1.20, 2.05)
[14,20] [36,117] [24,339] [12,47] [13,90] [79,500]
37-108 0.95 (0.62, 1.47) 1.10 (0.85, 1.42) 1.27 (0.95, 1.70) 1.10 (0.71, 1.70) 1.22 (0.75, 1.98) 1.28 (1.02, 1.59)
[32,95] [107,350] [59,607] [28,135] [21,166] [199,855]
>108 1.01 (0.79, 1.29) 1.08 (0.81, 1.44) 0.94 (0.69, 1.28) 1.07 (0.72, 1.59) 0.50 (0.28, 0.89) 0.98 (0.75, 1.28)
[139,389] [67,339] [48,554] [33,185] [13,251] [67,704]
aAdjusted for age, centre, total pregnancies, socioeconomic index, use of an IUD. All risks are relative to nonusers of any type of oral
contraceptives (based on 1,746 cases and 11,805 controls). 95% confidence intervals are in ( ), and number of cases and controls are in [ ].BREAST CANCER AND TYPES OF ORAL CONTRACEPTIVES 111
exposed cases and 20 and 29 exposed controls, respectively.
Oral contraceptives were grouped into those that contain
progestins that are 17-alpha-hydroxyprogesterone derivates
(medroxyprogesterone acetate and chlormadinone), and those
that are 19-nor-testosterone derivatives (all others except
megesterol). Relative risks in women who ever used these two
classes of formulations were estimated to be 1.16 (1.05, 1.29)
and 1.17 (1.05, 1.30), respectively. As shown in Table III,
relative risks in relation to months of use and months since
last use of these two classes of progestins are also similar.
Oral contraceptives with more than 0.08 mg mestranol or
more than 0.04 mg ethinyl estradiol were grouped together as
high dose products, and those with lower levels were con-
sidered low dose products. Relative risks of breast cancer in
women who ever used only low dose products, only high
dose products, and both high and low dose products were
estimated to be 1.10 (0.94, 1.29), 1.17 (1.03, 1.34), and 1.21
(0.99, 1.43), respectively. As shown in Table III, the relative
risks in relation to duration of use and months since last use
are not consistently higher in women who used only the high
dose preparations than in women who used only the low
dose products; and the trends in relative risk in relation to
these features of use are similar in both groups of users.
Similar trends were also observed in women who used both
high and low dose products (not shown). Based on the
glycogen deposition test (Dikey, 1984), oral contraceptives
with high and low doses of oestrogen were further classified
into those with relatively high and low doses of progestin
(Rosenblatt et al., 1991). This classification also did not
distinguish women at different risks of breast cancer. As in
Table I, for all four groups of oral contraceptives in Table
III, risks declined with time since last use in all categories of
duration of use, but no trends in risk with months of use
were evident after stratifying on months since last use (not
shown).
Estimates of the relative risk of breast cancer per year of
use of 18 different individual formulations are shown in
Table IV. Although the 95% confidence intervals of most
estimates include 1.0, the point estimates for 14 of the 18
preparations are greater than unity, and the lower 95%
confidence interval of seven of the estimates is 1.0, whereas
none of the upper 95% confidence limits are equal to or
lower than 1.0. A slightly increased relative risk of 1.08 (0.92,
1.28) was observed in women who ever used oral contracep-
tive brands of unknown type (based on 210 exposed cases
and 1,460 exposed controls). Since this value is above unity,
the exclusion of these subjects from Table IV is not an
explanation for the slightly higher relative risks associated
with most individual products.
Table IV also shows four pairs of relative risks per year of
use associated with oral contraceptives with equal doses of
ethinyl estradiol but different doses of the same progestin
(50 micrograms of ethinyl estradiol with 2.5 and 1.0mg
lynestrenol, with 4.0 and 3.0 mg norethisterone acetate, and
with 0.25 and 0.125mg d-norgesterol, and 30 micrograms
ethinyl estradiol with 0.15 and 0.125mg d-norgesterol). In
the latter three pairs, the relative risk is slightly greater for
the higher dose progestin preparation (1.09 vs 1.01, 1.02 vs
0.89, and 0.95 vs 0.81, respectively); the relative risks are
virtually the same (1.03 and 1.05) for two preparations with
different doses of lynestrenol. Also, there are two pairs of
relative risks per year of use associated with preparations
containing equal doses of progestin and different doses of
oestrogen (1.0mg lynestrenol with 100 and 75 micrograms
mestranol, and 0.125 mg d-norgesterol with 50 and 30 micro-
grams ethinyl estradiol), and in each pair the relative risk is
slightly greater for the preparation with the higher oestrogen
dose. Thus, five of six comparisons yielded results in the
same direction, although all of the differences were small and
not statistically significant.
Discussion
In a previous report of results from this study (WHO Col-
laborative Study of Neoplasia and Steroid Contraceptives,
1990), the relative risk of breast cancer in women who ever
used oral contraceptives was estimated to be 1.15 (1.02, 1.29).
Risk was highest in current and recent users, and decreased
with time since last exposure, after stratifying on duration of
use. Small increases in risk were also observed in relation to
use before age 25 and before the birth of a woman's first
child. These findings were based on interim analyses of data
on 2,116 cass and 12,077 controls. Since that report was
prepared, data collection for this study has terminated, and
the present report is based on analyses of data that include
638 additonal cases and 6,488 additional controls. Reanalysis
of the data yielded findings virtually identical to those
Table III Relative risksa of breast cancer in relation to months of use and months since last use of oral
contraceptives containing 17-m-hydroxyprogesterone and 19-nor-testosterone derived progestins, and low
and high doses of oestrogen
Months Progesterone derivative Dose of oestrogen
of use 17-x-hydroxyprogesterone 19-nor-testosterone Low Highb
1-12 1.06 (0.76, 1.48) 1.00 (0.85, 1.19) 1.07 (0.84, 1.36) 1.01 (0.81, 1.26)
[60,55] [206,2120] [89,928] [108,924]
13-36 0.85 (0.60, 1.21) 1.07 (0.89, 1.30) 0.98 (0.75, 1.27) 1.21 (0.98, 1.49)
[49,70] [154,1286] [74,812] [127,841]
37-60 1.26 (0.85, 1.85) 1.27 (1.02, 1.58) 1.10 (0.76, 1.59) 1.31 (1.02, 1.69)
[43,102] [119,730] [36,303] [91,447]
>60 1.25 (0.87, 1.79) 1.40 (1.19, 1.64) 1.69 (1.20, 2.38) 1.32 (0.96, 1.84)
[53,115] [265,1231] [50,204] [53,228]
Months since
last use
<4c 1.82 (0.88, 3.77) 1.63 (1.35, 1.98) 2.08 (1.55, 2.79) 1.58 (1.16, 2.15)
[13,21] [178,1066] [65,420] [61,363]
4-36 1.70 (0.93, 3.08) 1.45 (1.18, 1.77) 1.01 (0.69, 1.50) 1.57 (1.17, 2.10)
[19,34] [144,939] [31,420] [68,357]
37-108 1.20 (0.71, 1.47) 1.17 (1.00, 1.37) 1.15 (0.88, 1.49) 1.23 (0.99, 1.51)
[48,134] [251,1699] [76,703] [139,775]
>108 1.00 (0.78, 1.28) 0.85 (0.71, 1.01) 0.81 (0.62, 1.05) 0.89 (0.72, 1.11)
[125,353] [171,1663] [77,704) [111,945]
aAdjusted for age, centre, total pregnancies, socioeconomic index, use of an IUD. All risks are relative to
nonusers of any type of oral contraceptives (based on 1,746 cases and 11,805 controls). bHigh dose
formulations are defined as > 0.04mg ethinyl estradiol or > 0.08 mg mestranol. cIncludes current users.112 D.B. THOMAS et al.
Table IV Estimated relative risks of breast cancer per year of use of 18 different types of
combined oral contraceptives
Relative risk per
Micrograms Progestin Number of users year of usea
of oestrogen Type Mg Cases Controls (95% CI)
Mestranol
100 ethynodiol diacetate 1.0 58 229 1.02 (0.94, 1.10)
100 lynestrenol 1.0 5 21 1.22 (0.97, 1.54)
100 norethynodrel 2.5 7 20 1.02 (0.81, 1.27)
80 chlormadinone 2.0 189 504 1.03 (0.99, 1.07)
75 lynestrenol 1.0 24 256 1.04 (0.97, 1.12)
50 northisterone 1.0 118 1530 1.03 (1.00, 1.07)
Ethinyl estradiol
50 medroxyprogesterone 5.0 10 28 1.17 (0.89, 1.54)
acetate
50 ethynodial diacetate 1.0 16 123 0.99 (0.83, 1.18)
50 lynestrenol 2.5 19 159 1.03 (0.93, 1.14)
50 lynestrenol 1.0 10 134 1.05 (0.92, 1.19)
50 norethisterone acetate 4.0 21 142 1.09 (1.00, 1.19)
50 norethisterone acetate 3.0 23 156 1.01 (0.93, 1.09)
50 dl-norgesterol 0.5 105 1173 1.05 (1.01, 1.10)
50 d-norgesterol 0.25 122 639 1.02 (0.95, 1.09)
50 d-norgesterol 0.125 111 232 0.89 (0.84, 1.96)
35 norethisterone 0.5 36 75 1.06 (1.00, 1.11)
30 d-norgesterol 0.15 51 587 0.95 (0.85, 1.05)
30 d-norgesterol 0.125 10 39 0.81 (0.52, 1.26)
'Adjusted for age, centre, total pregnancies, socioeconomic index, use of an IUD, and
duration of use of other types of oral contraceptives.
previously reported and those updated results have thus not
been presented. In our previous report the conventional
causes of spurious associations were considered in detail, and
no specific sources ofbias ofconfounding were identified that
explained the main findings. These considerations will also
not be reiterated in this report.
The purpose of the additional analyses that serve as the
basis of this paper was to determine whether associations
between breast cancer and use of oral contraceptives vary
among preparations that contain different types and doses of
oestrogens and progestins. The associations observed in this
study between breast cancer and use of oral contraceptives
were virtually the same for mestranol and ethinyl estradiol
containing formulations. This is not surprising since mest-
ranol is metabolised to estradiol, and both exogenous
oestrogens thus result in the same biologically active com-
pound. Other studies have similarly found no difference in
relationships to breast cancer of products with these two
oestrogens (CASH, 1986; UK National Group, 1989; Vessey
et al., 1989). Similarly, norethisterone acetate, ethynodial
acetate, and lynestrenol are all converted to norethisterone,
and, as expected, no consistent differences in relative risks
associated with use of oral contraceptives that contain these
four progestins were found.
Progestins that are 17-alpha-hydroxyprogesterone
derivatives have been shown to cause benign and malignant
mammary tumours in beagles (Fraser & Holck, 1983), and
oral contraceptives that contain these compounds have been
removed from the market in most countries. This study was
conducted in some countries where these compounds are still
in use, thus affording an opportunity to assess their car-
cinogenicity for the human breast. The results clearly demon-
strate that oral contraceptives with these types of progestins
are no more strongly associated with an increased risk of
breast cancer than the 19-nor-testosterone derivatives. Also,
both in this study (WHO Collaborative Study of Neoplasia
and Steroid Contraceptives, 1991), and in a large population-
based case-control study in New Zealand (Paul et al., 1989;
Paul et al., 1990b) relative risk estimates were similar for
women who ever used the long acting injectable contracep-
tive, depot-medroxyprogesterone acetate (DMPA), a 17-
alpha-hydroxyprogesterone derivative, and for women who
ever used combined oral contraceptives that contain 19-nor-
testosterone derivatives. In the New Zealand study, both
relative risk estimates were 1.0, and in the present study these
estimates were 1.21 for users of DMPA, and 1.17 for users of
oral contraceptives with 19-nor-testosterone derivatives.
The findings regarding oral contraceptives that contain the
two different classes of progestins are of potential public
health importance. The thromboembolic diseases that have
been associated with use of oral contraceptives may be due to
the influence on blood clotting mechanisms of their con-
stituent progestins (Prentice & Thomas, 1987), and all of the
preparations that have been implicated contain 19-nor-
testosterone derivatives. If the 17-alpha-hydroxyprogesterone
derivatives are less, or no more, strongly related to thrombo-
embolic phenomenon than the 19-nor-testosterone compounds,
then use of oral contraceptives with chlormadinone or med-
roxyprogesterone acetate should be reconsidered. Additional
studies to attempt to replicate findings from this study are
thus warranted.
The relative risk of breast cancer was slightly higher in
women who ever used oral contraceptives with more than
0.4 mg ethinyl estradiol or more than 0.8 mg mestranol than
in users of lower dose preparations, but the difference was
small and readily explainable on the basis of chance, and
relative risk estimates in relation to duration of use and time
since last use were not consistently greater in users of the
high dose products. However, when individual formulations
were considered separately, slightly greater relative risks per
year of use were observed in relation to oral contraceptives
with relatively higher than lower doses of oestrogen and
progestin, although all differences are small, and each could
have occurred by chance.
The findings of the UK National Case-Control Study
Group (1989) are partially consistent with those from the
present investigation. Among women in that study who took
preparations with 50 micrograms ethinyl estradiol, those who
took formulations with 4 mg norethisterone acetate were at
higher relative risk than those who took formulations with
lower doses (1.4 vs 1.1, 1.2, and 1.1 for preparations with 4.0,
3.0, 2.5, and 1.0 mg, respectively). However, relative risks in
women who took oral contraceptives containing 30 micro-
grams ethinyl estradiol and 0.25 or 0.15 mg levonorgestrel
were 1.0 and 1.1, respectively; and in the Cancer and Steroid
Hormone Study (1986), relative risks were slightly higher in
women who used preparations with 1.0 mg norethisterone
and 50 micrograms mestranol than in women who used
preparations with the same dose of the progestin, but a
higher dose (80 micrograms) of the oestrogen (1.2 vs 1.0). ABREAST CANCER AND TYPES OF ORAL CONTRACEPTIVES 113
possible explanation for the inconsistencies with the present
findings is that in the estimation of relative risks from the
prior investigations, differences in duration of use of the
different types of oral contraceptives was not considered.
Also, all estimates of relative risks (like those from the
present investigation) are based on small numbers of users,
and are subject to considerable chance variation. Additional
investigations, or combined analyses of data from multiple
studies, are needed to clarify the role that specific combina-
tions of various oestrogens and progestins, in various doses,
may play in the genesis of breast cancer.
In summary, the findings from this study provide no
evidence that the risk of breast cancer in users of oral
contraceptives varies by the type of oestrogen or progestin
consumed. Women who used relatively low dose oral contra-
ceptives may be at slightly lower risk of breast cancer than
users of higher dose preparations, but the evidence for this is
not strong, and if such a difference in risk does exist, it is
small.
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